ARVN logo

Arvinas Inc. (ARVN)

$6.82

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ARVN

Market cap

$446607741

EPS

-0.1

P/E ratio

--

Price to sales

1.58

Dividend yield

--

Beta

1.815256

Price on ARVN

Previous close

$6.77

Today's open

$6.70

Day's range

$6.45 - $6.83

52 week range

$6.33 - $14.51

Profile about ARVN

CEO

Randy Teel

Employees

246

Headquarters

New Haven, CT

Exchange

Nasdaq Global Select

Shares outstanding

65485006

Issue type

Common Stock

ARVN industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ARVN

Arvinas to Present at Jefferies Global Healthcare Conference

NEW HAVEN, Conn., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 18 at 9:00 a.m. GMT/4:00 a.m. EST.

news source

GlobeNewsWire • Nov 11, 2026

news preview

Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting

– Data presentation to include safety, pharmacokinetics (PK), and pharmacodynamics (PD) from all patients, with preliminary efficacy from patients with T-cell lymphomas, in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) – NEW HAVEN, Conn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preliminary clinical data from the Phase 1 study of ARV-393 (zaloblideg) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) will be presented at the 2026 American Society of Hematology (ASH®) Annual Meeting, taking place December 12- 15, 2026, in New Orleans, Louisiana.

news source

GlobeNewsWire • Nov 4, 2026

news preview

What Arvinas (ARVN) Said on Its Q3 Earnings Call

Arvinas NASDAQ: ARVN outlined upcoming clinical milestones across its oncology and neurology pipeline during its third-quarter 2026 earnings call, while reporting lower operating expenses and a cash runway projected into the second half of 2028.

news source

MarketBeat • Nov 3, 2026

news preview

Arvinas, Inc. (ARVN) Q3 2026 Earnings Call Transcript

Arvinas, Inc. (ARVN) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 3, 2026

news preview

Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update

– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation – – Reaffirmed commitment to share clinical data from three Phase 1 programs - ARV-393, ARV-027 and ARV-6723 - in 4Q 2026 and 2027 – – Demonstrated novel oculomotor and biomarker movement with ARV-102 Phase 1 clinical data in patients with Parkinson's disease with oral presentation at MDS conference – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to a loss of $0.48 per share a year ago.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026

NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, November 3, 2026 at 8:00 a.m. ET.

news source

GlobeNewsWire • Oct 27, 2026

news preview

Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation

– $25,000 monetary award to recognize an emerging researcher or research team advancing targeted protein degradation – – Nominations open November 1, 2026, and close December 31, 2026; winner to be recognized in mid-2027 – NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the return of the Arvinas Early Career Researcher Award, which recognizes the research of an emerging researcher or research team bringing innovation, new approaches and creative thinking to the field of targeted protein degradation (TPD).

news source

GlobeNewsWire • Oct 27, 2026

news preview

Reasons Why Investors Should Consider Betting on Arvinas Stock

ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.

news source

Zacks Investment Research • Oct 13, 2026

news preview

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease

– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson's disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor function and changes in synaptic biomarkers –

news source

GlobeNewsWire • Oct 7, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Arvinas Inc.

Open an M1 investment account to buy and sell Arvinas Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ARVN on M1